Axonics sees Q4 revenue $85.6M-$86.0M, consensus $74.3M

Axonics reported preliminary unaudited revenue for the Q4. "This quarter’s record revenue result reflects the growing demand for our best-in-class incontinence products," said Raymond W. Cohen, CEO. "Our U.S. commercial team is continuing to take advantage of increased patient awareness and the overwhelmingly positive physician response to the Axonics F15 recharge-free sacral neuromodulation system while leveraging cross selling opportunities with Bulkamid. Our unique hydrogel generated another record revenue quarter and in fiscal year 2022, Bulkamid has been used to treat over 50,000 women with stress urinary incontinence." The preliminary results are unaudited and remain subject to adjustment.